MNKD vs. LGND, BCRX, FOLD, CLDX, INVA, DVAX, OPK, NVAX, GERN, and RGLS
Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
MannKind vs. Its Competitors
Ligand Pharmaceuticals (NASDAQ:LGND) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.
Ligand Pharmaceuticals currently has a consensus price target of $146.14, indicating a potential upside of 28.47%. MannKind has a consensus price target of $10.33, indicating a potential upside of 191.90%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, MannKind has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
MannKind has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
MannKind has a net margin of 10.12% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat MannKind's return on equity.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than MannKind. MarketBeat recorded 7 mentions for Ligand Pharmaceuticals and 2 mentions for MannKind. Ligand Pharmaceuticals' average media sentiment score of 0.81 beat MannKind's score of -1.01 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.
Summary
MannKind beats Ligand Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get MannKind News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MannKind Competitors List
Related Companies and Tools
This page (NASDAQ:MNKD) was last updated on 7/7/2025 by MarketBeat.com Staff
